JP2014523236A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014523236A5 JP2014523236A5 JP2014513035A JP2014513035A JP2014523236A5 JP 2014523236 A5 JP2014523236 A5 JP 2014523236A5 JP 2014513035 A JP2014513035 A JP 2014513035A JP 2014513035 A JP2014513035 A JP 2014513035A JP 2014523236 A5 JP2014523236 A5 JP 2014523236A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- gfp
- tumor
- expression cassette
- gene expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 42
- 230000014509 gene expression Effects 0.000 claims description 39
- 206010028980 Neoplasm Diseases 0.000 claims description 38
- 210000004881 tumor cell Anatomy 0.000 claims description 34
- 238000003776 cleavage reaction Methods 0.000 claims description 26
- 230000007017 scission Effects 0.000 claims description 26
- 241000701161 unidentified adenovirus Species 0.000 claims description 23
- 239000013598 vector Substances 0.000 claims description 22
- 229960000318 kanamycin Drugs 0.000 claims description 15
- 238000010367 cloning Methods 0.000 claims description 13
- 238000010276 construction Methods 0.000 claims description 12
- 230000000174 oncolytic effect Effects 0.000 claims description 12
- 230000010076 replication Effects 0.000 claims description 12
- 241000598171 Human adenovirus sp. Species 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 238000011144 upstream manufacturing Methods 0.000 claims description 11
- 230000006801 homologous recombination Effects 0.000 claims description 10
- 238000002744 homologous recombination Methods 0.000 claims description 10
- 229930027917 kanamycin Natural products 0.000 claims description 10
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 10
- 229930182823 kanamycin A Natural products 0.000 claims description 10
- 108091008146 restriction endonucleases Proteins 0.000 claims description 9
- 239000013605 shuttle vector Substances 0.000 claims description 9
- 230000002255 enzymatic effect Effects 0.000 claims description 8
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 claims description 6
- 229960000723 ampicillin Drugs 0.000 claims description 6
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 6
- 229960005091 chloramphenicol Drugs 0.000 claims description 6
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 6
- 108010048367 enhanced green fluorescent protein Proteins 0.000 claims description 6
- 239000003623 enhancer Substances 0.000 claims description 6
- 230000000977 initiatory effect Effects 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 229920001817 Agar Polymers 0.000 claims description 4
- 239000008272 agar Substances 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 230000017531 blood circulation Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 101150013749 18.5 gene Proteins 0.000 claims description 2
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropanol Chemical compound CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 241001135569 Human adenovirus 5 Species 0.000 description 41
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 10
- 241000700605 Viruses Species 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 102100039373 Membrane cofactor protein Human genes 0.000 description 3
- 210000003855 cell nucleus Anatomy 0.000 description 3
- 231100000304 hepatotoxicity Toxicity 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 description 2
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 108010017842 Telomerase Proteins 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 210000004081 cilia Anatomy 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000007056 liver toxicity Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 244000309459 oncolytic virus Species 0.000 description 2
- 210000004976 peripheral blood cell Anatomy 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 101710094396 Hexon protein Proteins 0.000 description 1
- 241000701190 Human adenovirus 11 Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 244000191761 Sida cordifolia Species 0.000 description 1
- 102000006612 Transducin Human genes 0.000 description 1
- 108010087042 Transducin Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 108070000030 Viral receptors Proteins 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 108010084938 adenovirus receptor Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110143385.3 | 2011-05-31 | ||
| CN2011101433853A CN102260712B (zh) | 2011-05-31 | 2011-05-31 | 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用 |
| PCT/CN2012/071757 WO2012163119A1 (zh) | 2011-05-31 | 2012-02-29 | 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014523236A JP2014523236A (ja) | 2014-09-11 |
| JP2014523236A5 true JP2014523236A5 (enExample) | 2015-08-20 |
| JP5943996B2 JP5943996B2 (ja) | 2016-07-05 |
Family
ID=45007547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014513035A Active JP5943996B2 (ja) | 2011-05-31 | 2012-02-29 | 腫瘍溶解性強化Ｂ型ヒトアデノウイルスＡｄ１１突然変異体の構築とその応用 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US9315827B2 (enExample) |
| EP (1) | EP2716764B1 (enExample) |
| JP (1) | JP5943996B2 (enExample) |
| CN (1) | CN102260712B (enExample) |
| WO (1) | WO2012163119A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102260712B (zh) * | 2011-05-31 | 2013-10-02 | 北京锤特生物科技有限公司 | 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用 |
| CA2903582C (en) | 2013-03-14 | 2021-06-08 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
| JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| CN106591368A (zh) * | 2016-10-12 | 2017-04-26 | 郑州大学 | 携带il‑15r/il‑15融合基因的b亚群腺病毒11载体及其构建和用途 |
| CA3045892A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| CN110093323B (zh) * | 2018-01-31 | 2024-01-30 | 上海元宋生物技术有限公司 | 重组溶瘤腺病毒OncoAd-P28GANK-E1A-△E1B及其构建方法和应用 |
| BR112020019942A2 (pt) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1816204B1 (en) * | 1999-05-17 | 2010-10-20 | Crucell Holland B.V. | Recombinant Adenovirus of the Ad26 serotype |
| US7741099B2 (en) * | 2004-10-13 | 2010-06-22 | Beth Israel Deaconess Medical Center Inc. | Adenoviral vectors and uses thereof |
| NZ555907A (en) * | 2004-11-16 | 2009-12-24 | Aeras Global Tb Vaccine Found | Multivalent vaccines comprising recombinant viral vectors |
| HUE031411T2 (en) * | 2007-03-02 | 2017-07-28 | Glaxosmithkline Biologicals Sa | New Methods and Preparations |
| CN102260712B (zh) * | 2011-05-31 | 2013-10-02 | 北京锤特生物科技有限公司 | 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用 |
-
2011
- 2011-05-31 CN CN2011101433853A patent/CN102260712B/zh active Active
-
2012
- 2012-02-29 EP EP12792810.9A patent/EP2716764B1/en active Active
- 2012-02-29 WO PCT/CN2012/071757 patent/WO2012163119A1/zh not_active Ceased
- 2012-02-29 JP JP2014513035A patent/JP5943996B2/ja active Active
-
2013
- 2013-11-29 US US14/093,078 patent/US9315827B2/en active Active
-
2016
- 2016-04-14 US US15/098,342 patent/US9932606B2/en active Active
-
2018
- 2018-02-25 US US15/904,408 patent/US10294493B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5943996B2 (ja) | 腫瘍溶解性強化Ｂ型ヒトアデノウイルスＡｄ１１突然変異体の構築とその応用 | |
| JP6817979B2 (ja) | 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体 | |
| JP2014523236A5 (enExample) | ||
| CN103614416B (zh) | 一种携带人穿膜肽p53与GM-CSF基因的重组溶瘤腺病毒及其用途 | |
| EP2137301B1 (en) | Adenovirus with mutations in the endoplasmic reticulum retention domain of the e3-19k protein and their use in cancer treatment. | |
| US11866724B2 (en) | Adenoviral vectors | |
| WO2008080003A2 (en) | Generation of oncolytic adenoviruses and uses thereof | |
| Yan et al. | Developing novel oncolytic adenoviruses through bioselection | |
| AU2002346084B2 (en) | Viral mutants that selectively replicate in targeted human cancer cells | |
| Gao et al. | A systematic comparison of the anti-tumoural activity and toxicity of the three Adv-TKs | |
| Wang et al. | Adenovirus vector-mediated single chain variable fragments target the nucleocapsid protein of porcine epidemic diarrhea virus and protect against viral infection in piglets | |
| WO2022192278A2 (en) | Muc16 promoter containing virus | |
| WO2025012636A1 (en) | Mutated adenoviruses with improved replication and their use for treating cancer | |
| WO2025133561A1 (en) | Adenoviruses | |
| Oya et al. | A novel conditionally replicative oncolytic adenovirus under the control of the SALL4 promoter inhibits the growth of rhabdoid tumors | |
| WO2024251286A1 (zh) | 溶瘤性hsv-1临床分离株、定向进化株、感染性克隆及应用 | |
| Lobby | Factors Impacting the Generation and Maintenance of CD8+ Tissue-Resident Memory T Cells Following Respiratory Immunization | |
| CN120738288A (zh) | 重组腺病毒载体和基于该载体的复制型腺病毒重组体及其构建方法 | |
| Sapre | Nanoparticle Cloaking of Viral Vectors for Enhanced Gene Delivery | |
| Young A | Development of an immunocompetent model of oncolytic adenoviral gene therapy for ovarian cancer. | |
| Hammer | Engineering of oncolytic adenoviruses for delivery by mesenchymal stem cells to pancreatic cancer |